The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-AnalysisReportar como inadecuado

The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Targeting immune cells or factors are effective for patients with solid tumors. Myeloid-derived suppressor cells MDSCs are known to have immunosuppressive functions, and the levels of MDSCs in patients with solid tumor are assumed to have prognostic values. This meta-analysis aimed at evaluating the relationship between MDSCs and the prognosis of patients with solid tumors. We searched articles in PUBMED and EMBASE comprehensively, updated to March 2016. Eight studies with 442 patients were included in the meta-analysis. We analyzed pooled hazard ratios HRs for overall survival OS, disease-free survival DFS and progression-free survival PFS. The results showed that MDSCs were associated with poor OS HR, 1.94; 95% confidence interval CI, 1.42–2.66; P < 0.0001 in patients with solid tumors. PFS-RFS HR, 1.85; 95% CI, 1.16–2.97; P = 0.01 also indicated the association between MDSCs and prognosis. The HRs and 95% CIs for OS in Asian and non-Asian patients were 2.53 95% CI 1.61–3.42, p < 0.00001 and 1.67 95% CI 1.14–2.46, p < 0.0001, respectively. We further analyzed the data according to tumor types. The combined HRs and 95% CIs for OS were 1.26 95% CI 1.10–1.44, p = 0.0003 for gastrointestinal GI cancer, 2.59 95% CI 1.69–3.98, p < 0.0001 for hepatocellular carcinoma HCC and 1.86 95% CI 1.26–2.75, p = 0.002 for other tumor types. In conclusion, MDSCs had a fine prognostic value for OS and PFS-RFS in patients with solid tumors. MDSCs could be used as biomarkers to evaluate prognosis in clinical practice.

Autor: Shuo Zhang , Xuelei Ma , Chenjing Zhu , Li Liu, Guoping Wang, Xia Yuan



Documentos relacionados